后TRIPS时代药品专利制度正当性的危机与反思  

Crisis and Reflection on the Legitimacy of Drug Patent System in the Post-TRIPS Era

作　　者：韩成芳 Han Chengfang(School of Law,Tsinghua University,Beijing 100084,China)

机构地区：[1]清华大学法学院,北京100084

出　　处：《科技与法律（中英文）》2021年第2期59-67,共9页Science Technology and Law（Chinese-English Version）

基　　金：清华大学科研项目“信息社会法治研究”(20205080090)。

摘　　要：尽管药品专利权是一项私人财产权,但因其与生命健康权有密切联系,故而具有较强的公共属性。在美国等西方发达国家主导下签订的TRIPS协议将药品专利的高标准保护扩展到了全世界,威胁了生命健康这一基本人权,由此进一步凸显了公共健康危机及发达国家与发展中国家之间的利益冲突。因此,有必要反思并重构后TRIPS时代药品专利的正当性并探索兼顾药品创新与药品可及性的有效机制,从而实现药品的可持续获得。Although drug patent right is a private property right,it has a strong public attribute because it is closely re⁃lated to the right to life and health.TRIPS signed under the leadership of the United States and other western devel⁃oped countries extends the high-standard protection of pharmaceutical patents to the whole world,threatening the ba⁃sic human right of life and health,thus further highlighting the public health crisis and the conflict of interest between developed and developing countries.Therefore,it is necessary to reflect and reconstruct the legitimacy of drug patents in the post-TRIPS era and explore an effective mechanism that takes both drug innovation and drug accessibility into account,so as to achieve sustainable access to drugs.

关 键 词：TRIPS协议 药品专利权 正当性 生命健康权 药品获得 

分 类 号：D923[政治法律—民商法学]